olomoucine

10/01/2012 - "Restoration of TFF1 expression in AGS cells suppressed tumor cell viability and arrested AGS cells in the G1-S transition phase after olomoucine treatment. "
08/01/2009 - "Is olomoucine, a weak CDK2 inhibitor, able to induce apoptosis in cancer cells?"
05/01/2003 - "The compounds 32a,b exhibited potent cell growth inhibitory activity against human cancer cell lines, but their CDK2 inhibitory activities were slightly poorer than olomoucine."
07/01/1997 - "Olomoucine failed to rapidly affect the phosphorylation of the Rb tumor-supressor gene product. "
11/01/1999 - "Therefore, our results give an impetus to continued research into olomoucine that might be a very useful chemotherapeutic strategy in the treatment of patients with mutant p53 tumors, at least in lymphoma patients."

03/17/2008 - "The increased localization of MMP-9 within epithelial cells at the wound edge was further enhanced by olomoucine while the expression of MMP-2 was reduced. "
08/15/2004 - "Inhibiting Cdk5 activity with olomoucine or a dominant negative construct, Cdk5T33, increased the concentration of Src(pY416), shifted its subcellular localization to the cell periphery and enhanced wound closure. "
03/17/2008 - "The Cdk5 inhibitor olomoucine promotes corneal debridement wound closure in vivo."
08/15/2004 - "Conversely, the Cdk5 inhibitor, olomoucine, accelerated debridement wound healing in organ cultured eyes of normal mice, caused migrating cells to separate from the epithelial cell sheet, and increased the level of activated Src(pY416) along the wound edge. "
03/17/2008 - "Olomoucine treatment significantly enhanced corneal wound closure without increasing inflammation or infiltration of polymorphonuclear leukocytes 18 h after wounding (p<0.05). "

11/01/2009 - "Microglial cells were treated with various concentrations of olomoucine after HSV-1 infection. "
11/01/2009 - "The aim of this work was to determine the influence of olomoucine on microglial activation during the inflammatory response after herpes simplex virus 1(HSV-1) infection. "
01/01/2016 - "The following results were obtained: (1) olomoucine increased survival in HSE mice; (2) olomoucine inhibited microglial activation and reduced HSV-1-induced cytokines release; (3) olomoucine prevented neural cells apoptosis and attenuated brain tissue pathological changes following HSV-1 infection; (4) olomoucine reduced brain edema and improved neurological function in HSE. "
11/01/2009 - "The following are the results of this work: (1) olomoucine reduced HSV-1-induced proliferation associated cyclin D1 expression; (2) olomoucine also induced microglial cells apoptosis early at 24 hours post-infection and inhibited the release of proinflammatory cytokine and chemokine, including tumor necrosis factor alpha and monocyte chemoattractant protein 1; and (3) olomoucine-induced apoptosis was caspase-dependent, and it also reduced the antiapoptotic protein Mcl-1. "

11/01/1999 - "Cellular effects of olomoucine in human lymphoma cells differing in p53 function."
11/01/1999 - "Therefore, our results give an impetus to continued research into olomoucine that might be a very useful chemotherapeutic strategy in the treatment of patients with mutant p53 tumors, at least in lymphoma patients."

01/01/2016 - "The following results were obtained: (1) olomoucine increased survival in HSE mice; (2) olomoucine inhibited microglial activation and reduced HSV-1-induced cytokines release; (3) olomoucine prevented neural cells apoptosis and attenuated brain tissue pathological changes following HSV-1 infection; (4) olomoucine reduced brain edema and improved neurological function in HSE. "